XAIR Overview

Beyond Air, Inc. is a commercial-stage medical device and biopharmaceutical company dedicated to harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. Its segments include Beyond Air, Beyond Cancer, and NeuroNos. It has received United States Food and Drug Administration approval for its first system, LungFit PH, for the treatment of term and near-term neonates with hypoxic respiratory failure. The Company is advancing its other LungFit systems in clinical trials for the treatment of severe lung infections such as viral community-acquired pneumonia (including COVID-19) and nontuberculous mycobacteria. It has also partnered with The Hebrew University of Jerusalem to advance a pre-clinical program dedicated to the treatment of autism spectrum disorder and other neurological disorders. Its product pipeline includes LungFit PH, LungFit PRO, LungFit GO, and others.

Wall Street analysts forecast XAIR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for XAIR is6.00 USD with a low forecast of 6.00 USD and a high forecast of 6.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Beyond Air Inc revenue for the last quarter amounts to 2.19M USD, increased 104.66

Beyond Air Inc. EPS for the last quarter amounts to -0.85 USD, decreased -71.28

Beyond Air Inc (XAIR) has 61 emplpoyees as of March 11 2026.

Today XAIR has the market capitalization of 8.68M USD.